It was reported that an increasing number of Indian patients who have survived COVID-19 develop mucormycosis, also known as black fungus, a rare condition that is fatal in 50 percent of cases.1 Pfizer, which will generate an estimated $26 billion in revenue from its vaccine this year and whose veterinarian CEO told shareholders that he expected “durable demand” to continue indefinitely, opposed the World Trade Organization’s plan to waive intellectual-property protections for manufacturing coronavirus vaccines, as did the European Union.
Weekly Review
Weekly Review
Weekly Review
It was reported that an increasing number of Indian patients who have survived COVID-19 develop mucormycosis, also known as black fungus, a rare condition that is fatal in 50 percent of cases.1 Pfizer, which will generate an estimated $26 billion in revenue from its vaccine this year and whose veterinarian CEO told shareholders that he expected “durable demand” to continue indefinitely, opposed the World Trade Organization’s plan to waive intellectual-property protections for manufacturing coronavirus vaccines, as did the European Union.